Ketenci Sema*, Demirkol Å?eyda, Sönmez Dilara, Giray Özlem, AydÄ±n Armagan, Kepenek Ata, Karapirli Kübra, Geyikoglu Ä°pek, Arda Sena, Berk C. Selim, Baghaki Sema, Demircan Günnur, YaylÄ±m Ä°lhan and AkÄ±n Demet
Many studies have shown that BDNF and TaqI can play a role in metabolic pathogenesis. This study aims to investigate the possible relationship between BDNF and TaqI gene polymorphisms, susceptibility to metabolic disease and psychopathological symptoms in female breast cancer patients. The potential pathophysiological relationship between metabolic syndrome (MetS) and breast cancer can be affected by the hormonal status of the cancer. For MetS, it is clinically important to determine the potential effects of different diagnostic criteria created by the hormone receptors (HR) status on the results of the metaanalysis. This large-scale prospective study was analyzed as a case-control study to determine the relationship between MetS and clinical outcomes in women with breast cancer, with 80 patients and 45 controls enrolled only in women. There was no significant difference in the genotype and allele distributions of polymorphism of both genes between the patient and control groups, but trends that made significant overall differences in metabolic pathogenesis were observed in the controls of patients with breast cancer. The findings suggest that the effects of gene polymorphisms on metabolic pathogenesis may be a pioneer in detecting negative symptoms in breast cancer diagnosis. As we know, metabolic pathway gene variations have been shown to be important in the development process of metabolic diseases. Many studies have shown that BDNF and TaqI gene polymorphisms are important in breast cancer. Recently, genetically related studies with cancer-targeting SNPs have focused on determining susceptibility, survival, complications, or responses to pharmacological intervention. The aim of our study is to investigate the possible relationship between susceptibility to metabolic disease and psychopathological symptoms.